Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Phase 2
50
about 5.1 years
40–80
3 sites in AL, MI, PA
What this study is about
This trial is testing whether ensifentrine, a medication, helps reduce inflammation markers in the sputum of people with COPD. Participants will receive either ensifentrine or a placebo for two periods of 8 weeks each. It lasts up to 24 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ensifentrine
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Respiratory System Agent (Phosphodiesterase 3 Inhibitors)
Primary: The change from baseline in sputum neutrophils at Week 8 (absolute change in cell numbers)
Secondary: The change from baseline in FEV1 after 4 weeks, The change from baseline in FEV1 after 8 weeks (post-dose), The change from baseline in FRC after 4 weeks, The change from baseline in FRC after 8 weeks (post-dose)., The change from baseline in FVC after 4 weeks, The change from baseline in FVC after 8 weeks (post-dose), The change from baseline in RV after 4 weeks, The change from baseline in RV after 8 weeks (post-dose)
Respiratory